Member Info for wherethefoxhat

paid to do

we should SEND a whip round for them

might as well

i feel that that find may well give Paddy and Bankrupt the weekend off

as sells
but
i think are buys

thought you were an endangered specie
assumed extinct
been a member for 3 years
lying dormant till this month with nothing but deramping comments
so a holder
or
not
not , i think

Matt Han**** could be the middle man

youve only got 90 mins to get chirping and deramp the price for the week end

MY MISTAKE
13.03 PM arrived

somethings wrong with my computer
i havnt received your 12.45 pm and 1.00 pm de-ramp yet

yes it is
BUT NOT EVERY 15 MINS !!!!!!

so youve been a member since 2020
with 2 posts up until today

you must be scarlet with rage about a potential placing
as youve posted EVERY 15 mins this morning telling us that fact
what does a paid de-ramper earn these days ?

any idea what time ?

if theres an interested party looking to buy or get involved they will be encouraging the price to go lower
so perfectly to plan

been here longer than you
just the comment about not wanting to be out before blockbuster RNS didnt balance with Sold all

only 6 weeks ago you posted these comments

I’m patiently waiting and not risking. I just don’t want to be out of GDR when the blockbuster RNS lands!
and
I think FOMO will kick in towards the end of the day and we’ll finish 30p+. We may wake up with an RNS on Monday morning and some people won’t risk it and want to be in. DYOR, good luck true holders
Well, joke aside, stay strong true long term holders. I believe we’ll be rewarded handsomely…

100k
50k
30k
many times

yes

https://www.macworld.com/article/1520846/apple-watch-glucose-monitoring-exploratory-design-group-breakthrough.html?utm_date=20230228092447&utm_campaign=Macworld%20iOS%20%20Tips%20and%20Trends&utm_content=Title%3A%20Secret%20Apple%20Watch%20team%20hails%20breakthrough%20in%20prick-less%20glucose%20monitoring&utm_term=Editorial%20-%20iOS%20Tips%20and%20Trends&utm_medium=email&utm_source=Adestra&huid=ed5b83e8-a23f-46cb-9f24-1a440e439003

this is why
Seagen, of Bothell, Wash., helped pioneer a class of cancer therapy known as antibody drug conjugates that works like a guided missile attacking tumors with toxic agents.

The therapies had been approved for cancers such as Hodgkin’s and other lymphomas, and more recently have shown promise in combination with an immunotherapy against other kinds of tumors including a form of breast cancer.

The potential in breast cancer could be particularly appealing to Pfizer, which has a top-selling drug, named Ibrance, treating the condition.

The Food and Drug Administration is reviewing whether to approve a combination of the Padcev antibody drug conjugate, from Seagen and Astellas Pharma Inc., and Merck’s Keytruda immunotherapy for treatment of advanced bladder cancer.